drugset / Trial / NCT06475846

A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults

NCT06475846

Phase 2 Completed 235 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the efficacy, and safety of HRS5580 for preventing of postoperative nausea and vomiting in adults. To explore the reasonable dosage of HRS5580 for postoperative nausea and vomiting.

Timeline

Start
2024-06-25
Primary completion
2024-10-29
Completion
2024-10-29

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS5580 Unknown
Comparator Ondansetron Other / unclassified

Indications

No indication recorded.